The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index; none of the 115 sources its claims cite is checked for support yet.
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Open accessAbstract
Human tumors progress despite the presence of tumor associated antigen (TAA)-specific T cells. Many different molecular and cellular mechanisms contribute to the failure of T cells to eradicate the tumor. These include immune suppressive networks that impair ongoing T cell function and enable tumor escape. Recent studies have started to reveal the nature of effector T cells in the tumor microenvironment. In this article we discuss T cell anergy, exhaustion, senescence, and stemness, and review the phenotype of dysfunctional T cell subsets and the underlying molecular mechanisms in the tumor microenvironments. We suggest that targeting T cell dysfunctional mechanisms and introducing/promoting T cell stemness are important approaches to treat patients with cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 115 cited sources checked · 0 supported · 0 flagged
None of the sources cited for this claim have been checked yet.
In the paper
“There is evidence indicating antigen specific, T cell-intrinsic dysfunction in the tumor microenvironment [15,16].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell anergy
What the sources say
- Not checked yetcites [15] Nazareth MR Broderick L Simpson-Abelson MR Kelleher RJ Jr Yokota SJ Bankert RB Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells J Immunol 2007 178 5552 5562 17442937 source
- Not checked yetcites [16] Broderick L Brooks SP Takita H Baer AN Bernstein JM Bankert RB IL-12 reverses anergy to T cell receptor triggering in human lung tumor-associated memory T cells Clin Immunol 2006 118 159 169 16271513 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This indicates a poor co-stimulatory, high co-inhibitory and therefore anergy-promoting environment.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell anergy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“T cell exhaustion may be a layered or progressive process to which T cells fall upon repeated activation.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell exhaustion
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“T cells acquiring multiple inhibitory surface molecules in persistent disease settings such as chronic infection [37,38] and malignancies [30,**39,40], which effectively prevent T cell activation.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell exhaustion
What the sources say
- Not checked yetcites [37] Wherry EJ Ha SJ Kaech SM Haining WN Sarkar S Kalia V Subramaniam S Blattman JN Barber DL Ahmed R Molecular signature of CD8+ T cell exhaustion during chronic viral infection Immunity 2007 27 670 684 17950003 source
- Not checked yetcites [38] Blackburn SD Shin H Haining WN Zou T Workman CJ Polley A Betts MR Freeman GJ Vignali DA Wherry EJ Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection Nat Immunol 2009 10 29 37 19043418 PMC2605166 source
- Not checked yetcites [30,**39,40]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In summary, tumor induced T cell anergy may be one of the immune evasion mechanisms in patients with cancer.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell anergy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes? Based: unclearA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, T cell anergy may be a functional mechanism in patients with cancer.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell anergy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIn the paper
“Given that members of the inhibitory B7 family are widely expressed by malignant cells and APCs within the human tumor microenvironment [7]”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell exhaustion
What the sources say
- Not checked yetcites [7] Zou W Chen L Inhibitory B7-family molecules in the tumour microenvironment Nat Rev Immunol 2008 8 467 477 18500231 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“It is generally accepted that T cells that are presented antigen along with suboptimal CD28 co-stimulation [4,5] and/or high co-inhibition [17] result in anergic phenotypes, as characterized by their low IL-2 production and cell cycle arrest at the G1/S phase.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell anergy
What the sources say
- Not checked yetcites [4] Schwartz RH A cell culture model for T lymphocyte clonal anergy Science 1990 248 1349 1356 2113314 source
- Not checked yetcites [5] Schwartz RH T cell anergy Annu Rev Immunol 2003 21 305 334 12471050 source
- Not checked yetcites [17] Greenwald RJ Boussiotis VA Lorsbach RB Abbas AK Sharpe AH CTLA-4 regulates induction of anergy in vivo Immunity 2001 14 145 155 11239447 source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesNone of the sources cited for this claim have been checked yet.
In the paper
“Exhausted CD8+ T cells were found in patients with melanoma [*31], ovarian cancer [9] and hepatocellular carcinoma (HCC) [30].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell exhaustion
What the sources say
- Not checked yetcites [*31]
- Not checked yetcites [9] source
- Not checked yetcites [30] Wu K Kryczek I Chen L Zou W Welling TH Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions Cancer Res 2009 69 8067 8075 19826049 PMC4397483 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIn the paper
“it is suggested that recruitment of SH2-domain containing protein tyrosine phosphatases (SHP-1 and/or SHP-2) to the immunoreceptor tyrosine-based switch motif (ITSM) within the PD-1 cytoplasmic tail inhibits signaling events, particularly PI3K/AKT activation, downstream signals of the T-cell receptor [34], and in turn results in T cell dysfunction.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell exhaustion
What the sources say
- Not checked yetcites [34] Riley JL PD-1 signaling in primary T cells Immunol Rev 2009 229 114 125 19426218 PMC3424066 source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 29
- Probably not a substantial claim. 4
In the paper
“Initial mouse studies have proposed that B7-H1/PD-1 signaling pathway mediates CD8+ T cell functional exhaustion in the context of chronic infection, and PD-1 was proposed to be a marker for exhausted T cells [*29].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell exhaustion
What the sources say
- Not checked yetcites [*29]
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Notably, activated T cells and effector T cells in the early stage may express PD-1 and remain functional [35,*36].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell exhaustion
What the sources say
- Not checked yetcites [35,*36]
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“It has been suggested that the anergy program is initiated by improper mTOR and Ras/MAPK signaling in the cell, a pathway which lies directly downstream of TCR/CD28 engagement.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell anergy
What the sources say
- Not checked yetcites [**19,20]
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Animal model studies have shown that introduction of B7-1 into tumors by transfection or blockade of inhibitory B7 family members can reduce tumor growth or result in spontaneous tumor rejection in vivo [7–13].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell anergy
What the sources say
- Not checked yetcites [7] Zou W Chen L Inhibitory B7-family molecules in the tumour microenvironment Nat Rev Immunol 2008 8 467 477 18500231 source
- Not checked yetcites [8] Blank C Brown I Peterson AC Spiotto M Iwai Y Honjo T Gajewski TF PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells Cancer Res 2004 64 1140 1145 14871849 source
- Not checked yetcites [9] source
- Not checked yetcites [10] Kryczek I Zou L Rodriguez P Zhu G Wei S Mottram P Brumlik M Cheng P Curiel T Myers L B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma J Exp Med 2006 203 871 881 16606666 PMC2118300 source
- Not checked yetcites [11] Chen L Ashe S Brady WA Hellstrom I Hellstrom KE Ledbetter JA McGowan P Linsley PS Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 Cell 1992 71 1093 1102 1335364 source
- Not checked yetcites [12] Gajewski TF B7-1 but not B7-2 efficiently costimulates CD8+ T lymphocytes in the P815 tumor system in vitro J Immunol 1996 156 465 472 8543795 source
- Not checked yetcites [13] Blank C Kuball J Voelkl S Wiendl H Becker B Walter B Majdic O Gajewski TF Theobald M Andreesen R Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro Int J Cancer 2006 119 317 327 16482562 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“it was demonstrated that human tumor cells and/or tumor associated APCs expressed B7-H1, and B7-H1/PD-1 pathway mediated immune suppression [**9]”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell exhaustion
What the sources say
- Not checked yetcites [**9]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In the course of defining exhausted PD-1+ T cells, T cell immunoglobulin and mucin-domain-containing molecule-3 (Tim-3) [39,41], lymphocyte-activation gene (LAG)-3 [38], and the B and T-cell lymphocyte attenuator (BTLA, CD272) [42,43] were found to be co-expressed with PD-1, and the co-expression has been strongly correlated with immune dysfunction in patients with cancer.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell exhaustion
What the sources say
- Not checked yetcites [39] source
- Not checked yetcites [41] Zhou Q Munger ME Veenstra RG Weigel BJ Hirashima M Munn DH Murphy WJ Azuma M Anderson AC Kuchroo VK Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia Blood 2011 117 4501 4510 21385853 PMC3099570 source
- Not checked yetcites [38] Blackburn SD Shin H Haining WN Zou T Workman CJ Polley A Betts MR Freeman GJ Vignali DA Wherry EJ Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection Nat Immunol 2009 10 29 37 19043418 PMC2605166 source
- Not checked yetcites [42] Fourcade J Sun Z Pagliano O Guillaume P Luescher IF Sander C Kirkwood JM Olive D Kuchroo V Zarour HM CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1 Cancer Res 2012 72 887 896 22205715 PMC3288235 source
- Not checked yetcites [43] Derre L Rivals JP Jandus C Pastor S Rimoldi D Romero P Michielin O Olive D Speiser DE BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination J Clin Invest 2010 120 157 167 20038811 PMC2799219 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The E3 ubiquiting ligase family can affect PI3K, mTOR, and Ras/MAPK signaling pathways and help to actively maintain anergy [21,23,24].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell anergy
What the sources say
- Not checked yetcites [21] Anandasabapathy N Ford GS Bloom D Holness C Paragas V Seroogy C Skrenta H Hollenhorst M Fathman CG Soares L GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells Immunity 2003 18 535 547 12705856 source
- Not checked yetcites [23] Jeon MS Atfield A Venuprasad K Krawczyk C Sarao R Elly C Yang C Arya S Bachmaier K Su L Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction Immunity 2004 21 167 177 15308098 source
- Not checked yetcites [24] Mueller DL E3 ubiquitin ligases as T cell anergy factors Nat Immunol 2004 5 883 890 15334084 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Homeostatic proliferation of anti-tumor T cells in a lymphopenic host both reverses anergy and promotes tumor rejection in vivo [14].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell anergy
What the sources say
- Not checked yetcites [14] Brown IE Blank C Kline J Kacha AK Gajewski TF Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection J Immunol 2006 177 4521 4529 16982889 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“The effects of this imbalance on the genetic reprogramming of these cells have been hypothesized to be mediated by NFAT homodimer formation and transcription of anergy-inducing genes [21,22].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell anergy
What the sources say
- Not checked yetcites [21] Anandasabapathy N Ford GS Bloom D Holness C Paragas V Seroogy C Skrenta H Hollenhorst M Fathman CG Soares L GRAIL: an E3 ubiquitin ligase that inhibits cytokine gene transcription is expressed in anergic CD4+ T cells Immunity 2003 18 535 547 12705856 source
- Not checked yetcites [22] Soto-Nieves N Puga I Abe BT Bandyopadhyay S Baine I Rao A Macian F Transcriptional complexes formed by NFAT dimers regulate the induction of T cell tolerance J Exp Med 2009 206 867 876 19307325 PMC2715123 source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✗ Asserted: fails✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The authors may not put it forward as true. The paper’s conclusions may not depend on it.
In the paper
“HCC-associated Tim-3+T cells expressed reduced CD28, suggesting that these cells may be early senescence stage [40].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell exhaustion
What the sources say
- Not checked yetcites [40] Li H Wu K Tao K Chen L Zheng Q Lu X Liu J Shi L Liu C Wang G Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma Hepatology 2012 56 1342 1351 22505239 source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In line with these limited reports in non-tumor system, human tumor associated Th17 cells expressed stem cell markers and exhibited stem cell like features.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell stemness
What the sources say
- Not checked yetcites [**71,**72]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Cell cycle controlling proteins p16, p21, and p53, normally inhibit cell cycle progression and have been shown to be accumulated in senescent cells [49–51].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell senescence
What the sources say
- Not checked yetcites [49] Passos JF Nelson G Wang C Richter T Simillion C Proctor CJ Miwa S Olijslagers S Hallinan J Wipat A Feedback between p21 and reactive oxygen production is necessary for cell senescence Mol Syst Biol 2010 6 347 20160708 PMC2835567 source
- Not checked yetcites [50] Rodier F Coppe JP Patil CK Hoeijmakers WA Munoz DP Raza SR Freund A Campeau E Davalos AR Campisi J Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion Nat Cell Biol 2009 11 973 979 19597488 PMC2743561 source
- Not checked yetcites [51] Beausejour CM Krtolica A Galimi F Narita M Lowe SW Yaswen P Campisi J Reversal of human cellular senescence: roles of the p53 and p16 pathways EMBO J 2003 22 4212 4222 12912919 PMC175806 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Telomere shortening is an inherent byproduct of cellular division, which affects cellular function and leads to cell senescence [48].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell senescence
What the sources say
- Not checked yetcites [48] Hayflick L Moorhead PS The serial cultivation of human diploid cell strains Exp Cell Res 1961 25 585 621 13905658 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“The concept of T cell stemness was initially stemmed from the observations that mouse central memory T cells are arrested at a pre-differentiation stage by transcriptional inhibitors and retain replicative potential and long-term production of effector T cells after a second antigen challenge [67].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell stemness
What the sources say
- Not checked yetcites [67] Fearon DT Manders P Wagner SD Arrested differentiation, the self-renewing memory lymphocyte, and vaccination Science 2001 293 248 250 11452114 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Bat3 localization at this protein region allows T cells continued proliferation and IFNγ production, an effect that was lost on Bat3 deficient cells and upon Tim-3 binding to galectin-9.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell senescence
What the sources say
- Not checked yetcites [66] Rangachari M Zhu C Sakuishi K Xiao S Karman J Chen A Angin M Wakeham A Greenfield EA Sobel RA Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion Nat Med 2012 18 1394 1400 22863785 PMC3491118 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In these studies, T cells co-expressing these surface molecules show a significant decrease in IL-2, IFNγ, and TNFα expression as well as cell cycle arrest, which defines T cell exhaustion.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell exhaustion
What the sources say
- Not checked yetcites [39] source
- Not checked yetcites [41] Zhou Q Munger ME Veenstra RG Weigel BJ Hirashima M Munn DH Murphy WJ Azuma M Anderson AC Kuchroo VK Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia Blood 2011 117 4501 4510 21385853 PMC3099570 source
- Not checked yetcites [38] Blackburn SD Shin H Haining WN Zou T Workman CJ Polley A Betts MR Freeman GJ Vignali DA Wherry EJ Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection Nat Immunol 2009 10 29 37 19043418 PMC2605166 source
- Not checked yetcites [42] Fourcade J Sun Z Pagliano O Guillaume P Luescher IF Sander C Kirkwood JM Olive D Kuchroo V Zarour HM CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1 Cancer Res 2012 72 887 896 22205715 PMC3288235 source
- Not checked yetcites [43] Derre L Rivals JP Jandus C Pastor S Rimoldi D Romero P Michielin O Olive D Speiser DE BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination J Clin Invest 2010 120 157 167 20038811 PMC2799219 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“It suggests that cancer associated Tim-3+ T cells may contain senescent cells and experience cell cycle arrest in G1/S phase.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell senescence
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In addition to phenotypic alteration, senescent T cells manifest defective killing abilities and the development of negative regulatory functions [52,53].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell senescence
What the sources say
- Not checked yetcites [52] Appay V Nixon DF Donahoe SM Gillespie GM Dong T King A Ogg GS Spiegel HM Conlon C Spina CA HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function J Exp Med 2000 192 63 75 10880527 PMC1887711 source
- Not checked yetcites [53] Akbar AN Henson SM Are senescence and exhaustion intertwined or unrelated processes that compromise immunity? Nat Rev Immunol 2011 11 289 295 21436838 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“A promising aspect is that clinical blockade of B7-H1/PD-1, the key T cell exhaustion pathway, may rescue T cell effector functions in vivo, and results in significant objective clinical responses [32,33].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell exhaustion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“human HCC- associated T cells highly express Tim-3 and cyclin dependent kinase inhibitors, and interact with galectin-9+myeloid APCs. These cells fail to enter the cell cycle [40].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell senescence
What the sources say
- Not checked yetcites [40] Li H Wu K Tao K Chen L Zheng Q Lu X Liu J Shi L Liu C Wang G Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma Hepatology 2012 56 1342 1351 22505239 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“it has been postulated that the human leukocyte antigen (HLA)-B-associated transcript 3 (Bat3) modulates Tim-3 function on T cells by interacting with Tim-3 cytoplasmic tail [66].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell senescence
What the sources say
- Not checked yetcites [66] Rangachari M Zhu C Sakuishi K Xiao S Karman J Chen A Angin M Wakeham A Greenfield EA Sobel RA Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion Nat Med 2012 18 1394 1400 22863785 PMC3491118 source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Senescent T cells are characterized by telomere shortenings, phenotypic change (loss of CD28 expression), and cell cycle arrest [46,47] (Fig. 1).”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell senescence
What the sources say
- Not checked yetcites [46] Adibzadeh M Pohla H Rehbein A Pawelec G Long-term culture of monoclonal human T lymphocytes: models for immunosenescence? Mech Ageing Dev 1995 83 171 183 8583835 source
- Not checked yetcites [47] Effros RB Replicative senescence in the immune system: impact of the Hayflick limit on T-cell function in the elderly Am J Hum Genet 1998 62 1003 1007 9545415 PMC1377102 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Phenotypically, senescent CD28−/dimCD8+T cells are observed in patients with lung cancers [57], head and neck cancer [58].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell senescence
What the sources say
- Not checked yetcites [57] Meloni F Morosini M Solari N Passadore I Nascimbene C Novo M Ferrari M Cosentino M Marino F Pozzi E Foxp3 expressing CD4+ CD25+ and CD8+CD28− T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma Hum Immunol 2006 67 1 12 16698419 source
- Not checked yetcites [58] Tsukishiro T Donnenberg AD Whiteside TL Rapid turnover of the CD8(+)CD28(−) T-cell subset of effector cells in the circulation of patients with head and neck cancer Cancer Immunol Immunother 2003 52 599 607 12827303 PMC11032778 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“In a mouse model, CD44lowCD62Lhigh memory CD8+ T cells express high levels of stem cell antigen-1 (Sca-1), Bcl-2 and common IL-2 and IL-15 receptor β chain (CD122). Because these cells showed robust self-renewal and the multipotent capacity to generate central memory and effector memory T cells, they were designated T memory stem cells [69].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell stemness
What the sources say
- Not checked yetcites [69] Zhang Y Joe G Hexner E Zhu J Emerson SG Host-reactive CD8+ memory stem cells in graft-versus-host disease Nat Med 2005 11 1299 1305 16288282 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“This suggests that cells in younger patients may become senescent, and chronic activation and proliferation may still cause T cell senescence [55].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell senescence
What the sources say
- Not checked yetcites [55] Vallejo AN Weyand CM Goronzy JJ T-cell senescence: a culprit of immune abnormalities in chronic inflammation and persistent infection Trends Mol Med 2004 10 119 124 15102354 source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Galectin-9 induces intracellular calcium flux, aggregation and death of Th1 cells in Tim-3-dependent manner [65].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell senescence
What the sources say
- Not checked yetcites [65] Zhu C Anderson AC Schubart A Xiong H Imitola J Khoury SJ Zheng XX Strom TB Kuchroo VK The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity Nat Immunol 2005 6 1245 1252 16286920 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“It is arguable but experimentally operative that PD-1 may be a marker for exhausted cells, Tim-3 and KLRG-1 may be markers for senescent cells, and mouse stem-like T cells may express Sca-1 [70].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > Conclusions
What the sources say
- Not checked yetcites [70] Gattinoni L Zhong XS Palmer DC Ji Y Hinrichs CS Yu Z Wrzesinski C Boni A Cassard L Garvin LM Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells Nat Med 2009 15 808 813 19525962 PMC2707501 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“it is evident that B7-H1/PD-1 and Tim-3/galectin-9 signaling pathways may synergistically and/or additively mediate T cell dysfunction, and simultaneous blockade of these pathways may result in improved T cell immunity.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > Conclusions
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Human Th17 cells were shown to give rise to distinct Th lineages, as measured through the expression of IFNγ, and Foxp3+ cells, heightened self-renewal, and survival capabilities [71,72].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell stemness
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Interestingly, Th17 cells retain a stem cell-like phenotype through the coordinated effects of HIF1α/Notch/Bcl-2 and are also potent anti-tumor effectors [71], suggesting that stemness might correlate with better immune responses.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell stemness
What the sources say
- Not checked yetcites [71] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Human Th17 cells have certain “stem cell properties” at the genetic, molecular and functional levels, and are long-lived cells.”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell stemness
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“When measured for their biological activity, mouse and human Th17 cells displayed greater survival potential, persistence as well as the ability of repopulating sub-lethally irradiated mice [**71,**72].”
§ T cell anergy, exhaustion, senescence and stemness in the tumor microenvironment > T cell stemness
What the sources say
- Not checked yetcites [**71,**72]
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper relies on this without support.
Human tumors progress despite the presence of tumor-associated antigen-specific T cells.
“Human tumors progress despite the presence of tumor associated antigen (TAA)-specific T cells.”
The paper relies on this without support.
T cell exhaustion occurs when T cells are chronically activated at sites of chronic inflammation, such as cancer, autoimmunity, and chronic infection.
“T cell exhaustion occurs when T cells are chronically activated at sites of chronic inflammation, such as cancer, autoimmunity, and chronic infection.”
The authors state this as an assumption.
The tumor microenvironment provides the necessary conditions for effector T cells to become functionally exhausted and to maintain this state during disease progression.
“Nonetheless, it is assumed that the tumor microenvironment provides the necessary conditions for effector T cells to become functionally exhausted as well as being able to maintain this state during disease progression.”
The paper relies on this without support.
These markers are not mutually exclusive or inclusive in a given T cell subset.
“However, these markers are not mutually exclusive and inclusive in a given T cell subset.”
The paper relies on this without support.
PD-1+ cells may express Tim-3 and LAG-3.
“PD-1+ cells may express Tim-3 and LAG-3.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Exhausted T cells are usually CM/EM T cells that have been chronically stimulated [341].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [341]
Experimental — accuracy not yet measuredIn the citing paper
“More recent studies have shown that, during aging, the cytotoxic activity of immune cells decreases, and the expression of functional molecules associated with cytotoxic activity, such as interferon gamma (IFN-γ), granzyme B, and perforin, is also reduced [31–34] (Table 1).”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [31]
In the citing paper
“T cell senescence is irreversible, as opposed to their anergy and exhaustion, both of which are considered reversible [31, 38–40].”
From Immunosenescence: a key player in cancer development (2020) · cites this paper as [31]
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
The serial cultivation of human diploid cell strains
Hayflick, L., & Moorhead, P. S. (1961) · Experimental Cell Research · doi:10.1016/0014-4827(61)90192-6 · Cited by 8,508
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Wherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion
Rodier, F., Coppé, J.-P., Patil, C. K., Hoeijmakers, W. A. M., Muñoz, D. P., Raza, S. R., Freund, A., Campeau, E., Davalos, A. R., & Campisi, J. (2009) · Nature Cell Biology · doi:10.1038/ncb1909 · Cited by 2,232
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Blackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 750
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 132
Molecular profiling of CD8 T cells in autochthonous melanoma identifies Maf as driver of exhaustion
Giordano, M., Henin, C., Maurizio, J., Imbratta, C., Bourdely, P., Buferne, M., Baitsch, L., Vanhille, L., Sieweke, M. H., Speiser, D. E., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201490786 · Cited by 132
Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients
Wei, X. L., Jin, Y., Tian, Y., Zhang, H., Wu, J., Lü, W., & Lu, X. (2015) · Tumor Biology · doi:10.1007/s13277-015-4538-0 · Cited by 133
CEACAM1 structure and function in immunity and its therapeutic implications
Kim, W. M., Huang, Y., Gandhi, A. K., & Blumberg, R. S. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101296 · Cited by 127
Human cell‐based artificial antigen‐presenting cells for cancer immunotherapy
Butler, M. O., & Hirano, N. (2013) · Immunological Reviews · doi:10.1111/imr.12129 · Cited by 131
Wei, J. S., Kuznetsov, I. B., Zhang, S., Song, Y., Asgharzadeh, S., Sindiri, S., Wen, X., Patidar, R., Najaraj, S., Walton, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0599 · Cited by 122
Advances in NK cell production
Fang, F., Xie, S., Chen, M., Li, Y., Yue, J., Ma, J., Shu, X., He, Y., Xiao, W., & Tian, Z. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00808-3 · Cited by 132
Self-citationTissues, not blood, are where immune cells function
Färber, D. L. (2021) · Nature · doi:10.1038/d41586-021-01396-y · Cited by 121
Moon, E. K., Ranganathan, R., Eruslanov, E. B., Kim, S., Newick, K., O’Brien, S., Lo, A., Liu, X., Zhao, Y., & Albelda, S. Μ. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1070 · Cited by 126
Stephen, T. L., Rutkowski, M. R., Allegrezza, M. J., Perales‐Puchalt, A., Tesone, A. J., Svoronos, N., Nguyen, J. M., Sarmin, F., Borowsky, M. E., Tchou, J. C., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.012 · Cited by 120
CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma
Gu, Y., Li, X., Bi, Y., Zheng, Y., Wang, J., Li, X., Huang, Z., Chen, L., Huang, Y., & Huang, Y. (2020) · Aging · doi:10.18632/aging.102656 · Cited by 119
The impact of senescence-associated T cells on immunosenescence and age-related disorders
Fukushima, Y., Minato, N., & Hattori, M. (2018) · Inflammation and Regeneration · doi:10.1186/s41232-018-0082-9 · Cited by 118
HCC-Derived Exosomes: Critical Player and Target for Cancer Immune Escape
Han, Q., Zhao, H., Yu, J., Yin, C., & Zhang, J. (2019) · Cells · doi:10.3390/cells8060558 · Cited by 120
Immune landscape of papillary thyroid cancer and immunotherapeutic implications
Na, K. J., & Choi, H. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0532 · Cited by 116
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 113
The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy
Sun, H., & Sun, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02354 · Cited by 121
Self-citationThe Single-Cell Phenotypic Identity of Human CD8+ and CD4+ T Cells
Brummelman, J., Pilipow, K., & Lugli, E. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.05.007 · Cited by 113
Zhao, L., Liu, Y., Zhang, S., Wei, L., Cheng, H., Wang, J., & Wang, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04821-w · Cited by 115
Ma, P., Beatty, P. L., McKolanis, J., Brand, R. E., Schoen, R. E., & Finn, O. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01401 · Cited by 108
T‐cell Immunoglobulin and ITIM Domain Contributes to CD 8+ T‐cell Immunosenescence
Song, Y., Wang, B., Song, R., Yu, H., Wang, D., Li, Y., Jiang, Y. Y., Xu, L., Ma, Y., Zheng, H., et al. (2018) · Aging Cell · doi:10.1111/acel.12716 · Cited by 109
Loschinski, R., Böttcher, M., Stoll, A., Bruns, H., Mackensen, A., & Mougiakakos, D. (2018) · Oncotarget · doi:10.18632/oncotarget.24442 · Cited by 109
Zhang, Y., & Ertl, H. C. J. (2016) · Oncotarget · doi:10.18632/oncotarget.7818 · Cited by 105
TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals
Manfredi, F., Cianciotti, B. C., Potenza, A., Tassi, E., Noviello, M., Biondi, A., Ciceri, F., Bonini, C., & Ruggiero, E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01689 · Cited by 108
Zhang, Y., & Ertl, H. C. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00032 · Cited by 102
Induction of anergic or regulatory tumor-specific CD4+ T cells in the tumor-draining lymph node
Alonso, R., Flament, H., Lemoine, S., Sedlik, C., Bottasso, E., Péguillet, I., Prémel, V., Denizeau, J., Salou, M., Darbois, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04524-x · Cited by 102
Obesity results in adipose tissue T cell exhaustion
Porsche, C. E., DelProposto, J. B., Geletka, L. M., O’Rourke, R. W., & Lumeng, C. N.-K. (2021) · JCI Insight · doi:10.1172/jci.insight.139793 · Cited by 104
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges
Kunimasa, K., & Goto, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21020597 · Cited by 106
Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy
Tang, H., Zhu, M., Qiao, J., & Fu, Y. (2017) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.13 · Cited by 97
Russell, S., Lamprecht, D. A., Mandizvo, T., Jones, T., Naidoo, V., Addicott, K. W., Moodley, C., Ngcobo, B., Crossman, D. K., Wells, G., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.034 · Cited by 103
CD8+ Tregs revisited: A heterogeneous population with different phenotypes and properties
Niederlová, V., Tsyklauri, O., Chadimová, T., & Štěpánek, O. (2021) · European Journal of Immunology · doi:10.1002/eji.202048614 · Cited by 99
Extremely Differentiated T Cell Subsets Contribute to Tissue Deterioration During Aging
Soto‐Heredero, G., Heras, M. M. G. D. L., Escrig-Larena, J. I., & Mittelbrunn, M. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101721-064501 · Cited by 96
Liu, R., Yuan, W., Zeng, Q., Chan, K., Xiao, C., Zhao, X., Chen, M., Ouyang, F., Chen, D., Zheng, L., et al. (2015) · Hepatology · doi:10.1002/hep.28020 · Cited by 97
Immunotherapy of cancers comes of age
Yousefi, H., Yuan, J. D., Keshavarz‐Fathi, M., Murphy, J. F., & Rezaei, N. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1366315 · Cited by 97
Regulation of murine NK cell exhaustion through the activation of the DNA damage repair pathway
Álvarez, M., Simonetta, F., Baker, J. B., Pierini, A., Wenokur, A. S., Morrison, A. R., Murphy, W. J., & Negrin, R. S. (2019) · JCI Insight · doi:10.1172/jci.insight.127729 · Cited by 96
Novel TCR-based biologics: mobilising T cells to warm ‘cold’ tumours
Lowe, K. L., Cole, D. K., Kenefeck, R., OKelly, I., Lepore, M., & Jakobsen, B. K. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.06.001 · Cited by 95
The immune landscape of common CNS malignancies: implications for immunotherapy
Ott, M., Prins, R. M., & Heimberger, A. B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00518-9 · Cited by 96
Reprogramming the tumor microenvironment by genome editing for precision cancer therapy
Liu, K., Cui, J., Zhan, Y., Ouyang, Q., Lu, Q., Yang, D., Li, X., & Yin, J. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01561-5 · Cited by 100
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy
Śledzińska, A., Menger, L., Bergerhoff, K. F., Peggs, K. S., & Quezada, S. A. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.008 · Cited by 95
The 3 I’s of immunity and aging: immunosenescence, inflammaging, and immune resilience
Wrona, M. V., Ghosh, R. B., Coll, K., Chun, C., & Yousefzadeh, M. J. (2024) · Frontiers in Aging · doi:10.3389/fragi.2024.1490302 · Cited by 107
Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy
Zuazo, M., Arasanz, H., Bocanegra, A., Fernández, G., Chocarro, L., Vera, R., Kochan, G. T., & Escors, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.586907 · Cited by 97
Alemohammad, H., Najafzadeh, B., Asadzadeh, Z., Baghbanzadeh, A., Ghorbaninezhad, F., Najafzadeh, A., Safarpour, H., Bernardini, R., Brunetti, O., Sonnessa, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112516 · Cited by 92
Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy
Liu, Q., Duo, Y., Fu, J., Qiu, M., Sun, Z., Adah, D., Kang, J., Xie, Z., Fan, T., Bao, S., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101023 · Cited by 93
Harnessing nanomedicine to overcome the immunosuppressive tumor microenvironment
Sun, B., Hyun, H., Li, L., & Wang, A. Z. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0424-4 · Cited by 91
Miar, A., Arnaiz, E., Bridges, E., Beedie, S., Cribbs, A. P., Downes, D. J., Beagrie, R., Rehwinkel, J., & Harris, A. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2306 · Cited by 86
CD226hiCD8+ T Cells Are a Prerequisite for Anti-TIGIT Immunotherapy
Jin, H., Ko, M., Choi, D., Kim, J. H., Lee, D.-H., Kang, S.-H., Kim, I., Lee, H. J., Choi, E. K., Kim, K., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0877 · Cited by 85
Current status of skin cancers with a focus on immunology and immunotherapy
Kohnehshahri, M. K., Sarkesh, A., Khosroshahi, L. M., HajiEsmailPoor, Z., Aghebati‐Maleki, A., Yousefi, M., & Maleki, L. A. (2023) · Cancer Cell International · doi:10.1186/s12935-023-03012-7 · Cited by 86
Nair, R., Somasundaram, V., Kuriakose, A., Krishn, S. R., Raben, D., Salazar, R. L., & Nair, P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1548234 · Cited by 100
Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes
Long, S. A., Thorpe, J., Herold, K. C., Ehlers, M. R., Sanda, S., Lim, N., Linsley, P. S., Nepom, G. T., & Harris, K. M. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.07.007 · Cited by 84
Ma, F., Vayalil, J., Lee, G., Wang, Y., & Peng, G. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003217 · Cited by 85
Cichocki, F. M., Bjordahl, R., Goodridge, J. P., Mahmood, S., Gaidarova, S., Abujarour, R., Davis, Z., Merino, A. M., Tuininga, K., Wang, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35127-2 · Cited by 90
Akagi, J., & Baba, H. (2018) · Oncology Reports · doi:10.3892/or.2018.6841 · Cited by 80
T-cell exhaustion correlates with improved outcomes in kidney transplant recipients
Fribourg, M., Anderson, L., Fischman, C. J., Cantarelli, C., Perin, L., Manna, G. L., Rahman, A. H., Burrell, B. E., Heeger, P. S., & Cravedi, P. (2019) · Kidney International · doi:10.1016/j.kint.2019.01.040 · Cited by 81
The diversity of CD8+ T cell dysfunction in cancer and viral infection
Galluzzi, L., Smith, K. N., Liston, A., & Garg, A. D. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01161-6 · Cited by 94
Richer, M. J., Lang, M. L., & Butler, N. S. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600847 · Cited by 77
Machicote, A., Belén, S., Baz, P., Billordo, L. A., & Fainboim, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02788 · Cited by 81
Özkazanç, D., Yöyen-Ermiş, D., Tavukçuoğlu, E., Büyükaşık, Y., & Esendağlı, G. (2016) · Immunology · doi:10.1111/imm.12665 · Cited by 76
Miyamoto, C., Kojo, S., Yamashita, M., Moro, K., Lacaud, G., Shiroguchi, K., Taniuchi, I., & Ebihara, T. (2019) · Nature Communications · doi:10.1038/s41467-019-08365-0 · Cited by 76
Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives
Raimondo, S., Pucci, M., Alessandro, R., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072286 · Cited by 79
The twilight of the immune system: The impact of immunosenescence in aging
Feehan, J., Tripodi, N., & Apostolopoulos, V. (2021) · Maturitas · doi:10.1016/j.maturitas.2021.02.006 · Cited by 77
Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy
Tang, Q., Yang, S., He, G., Zheng, H., Zhang, S., Liu, J., Wei, S., Fan, Q., Peng, X., Li, X., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215823 · Cited by 77
Comparing photoporation and nucleofection for delivery of small interfering RNA to cytotoxic T cells
Wayteck, L., Xiong, R., Braeckmans, K., Smedt, S. C. D., & Raemdonck, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.002 · Cited by 79
Immune-checkpoint inhibitors for combating T-cell dysfunction in cancer
Grywalska, E., Pasiarski, M., Góźdź, S. S., & Roliński, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s150817 · Cited by 82
Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond
Teoh, S. T., & Lunt, S. Y. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1406 · Cited by 77
B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling
Rieder, S. A., Wang, J., White, N. M., Qadri, A. N., Ménard, C., Stephens, G. L., Karnell, J. L., Rudd, C. E., & Kolbeck, R. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0361-7 · Cited by 73
Wilson, D. S., Damo, M., Hirosue, S., Raczy, M. M., Brünggel, K., Diaceri, G., Quaglia-Thermes, X., & Hubbell, J. A. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0424-1 · Cited by 71
Chen, H., Luan, X., Paholak, H. J., Burnett, J., Stevers, N. O., Sansanaphongpricha, K., He, M., Chang, A. E., Li, Q., & Sun, D. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0190 · Cited by 71
Personalized medicine and back–allogeneic exosomes for cancer immunotherapy
Samuel, M., & Gabrielsson, S. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12963 · Cited by 72
Zuazo, M., Gato, M., Llorente, N., Ibáñez-Vea, M., Arasanz, H., Kochan, G. T., & Escors, D. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.11 · Cited by 72
Exhausted T cells and epigenetic status
Zeng, Z., Wei, F., & Ren, X. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0338 · Cited by 73
Human intratumoral therapy: Linking drug properties and tumor transport of drugs in clinical trials
Huang, A., Pressnall, M. M., Lu, R., Huayamares, S. G., Griffin, J. D., Groer, C. E., DeKosky, B. J., Forrest, M. L., & Berkland, C. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.029 · Cited by 69
Hallmarks and Biomarkers of Skin Senescence: An Updated Review of Skin Senotherapeutics
Bulbiankova, D., Díaz‐Puertas, R., Álvarez‐Martínez, F. J., Herranz‐López, M., Barrajón‐Catalán, E., & Micol, V. (2023) · Antioxidants · doi:10.3390/antiox12020444 · Cited by 72
T Cell Exhaustion and CAR‐T Immunotherapy in Hematological Malignancies
Tang, L., Zhang, Y., Hu, Y., & Mei, H. (2021) · BioMed Research International · doi:10.1155/2021/6616391 · Cited by 72
Li, X., Wang, R., Fan, P., Yao, X., Qin, L., Peng, Y., Ma, M., Asley, N., Chang, X., Feng, Y., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01066 · Cited by 68
Zhang, Y., Li, Y., Chen, K., Qian, L. M., & Wang, P. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01972-2 · Cited by 65
Turner, J. E., & Brum, P. C. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/4234765 · Cited by 66
Checkpoint Inhibition in Myeloma: Opportunities and Challenges
Costa, F., Das, R., Bailur, J. K., Dhodapkar, K. M., & Dhodapkar, M. V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02204 · Cited by 66
PD1 pathway in immune-mediated myopathies
Knauß, S., Preuße, C., Allenbach, Y., Léonard-Louis, S., Touat, M., Fischer, N., Radbruch, H., Mothes, R., Matyash, V., Boehmerle, W., et al. (2019) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000558 · Cited by 66
Peng, H., Wu, X., Zhong, R., Tao, Y., Cai, X., Liu, J., Wen, Y., Ao, Y., Chen, J., Li, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.750046 · Cited by 63
The controversial role of senescence-associated secretory phenotype (SASP) in cancer therapy
Cao, L., Li, K., Li, Q., Tong, Q., Wang, Y., & Huang, L. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02475-8 · Cited by 79
Role of immune system in tumor progression and carcinogenesis
Upadhyay, S., Sharma, N., Gupta, K. B., & Dhiman, M. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26663 · Cited by 65
ITCH as a potential therapeutic target in human cancers
Yin, Q., Wyatt, C. J., Han, T., Smalley, K. S. M., & Wan, L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.03.003 · Cited by 60
Wurzer, H., Hoffmann, C., Absi, A. A., & Thomas, C. (2019) · Cells · doi:10.3390/cells8050463 · Cited by 62
Senescence in the Development and Response to Cancer with Immunotherapy: A Double-Edged Sword
Battram, A. M., Bachiller, M., & Martín-Antonio, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124346 · Cited by 66
Enhanced development of functional human NK cells in NOD‐ scid‐IL2rg null mice expressing human IL15
Aryee, K., Burzenski, L. M., Yao, L., Keck, J., Greiner, D. L., Shultz, L. D., & Brehm, M. A. (2022) · The FASEB Journal · doi:10.1096/fj.202200045r · Cited by 63
MUCIN-4 (MUC4) is a novel tumor antigen in pancreatic cancer immunotherapy
Gautam, S. K., Sushil Kumar, K., Dam, V., Ghersi, D., Jain, M., & Batra, S. K. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101391 · Cited by 59
Adu‐Berchie, K., Brockman, J. M., Liu, Y., To, T., Zhang, D. K. Y., Najibi, A. J., Binenbaum, Y., Stafford, A. G., Dimitrakakis, N., Sobral, M. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39330-7 · Cited by 60
Suppression of T cell responses in the tumor microenvironment
Frey, A. B. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.08.096 · Cited by 60
Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer
Hou, X., Zheng, Z., Wei, J., & Zhao, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1030745 · Cited by 61
The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors
Wang, L., Zhang, L., Dunmall, L. C., Wang, Y. Y., Fan, Z., Cheng, Z., & Wang, Y. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216871 · Cited by 59
The tumor microenvironment shapes the molecular characteristics of exhausted CD8+ T cells
Cheng, H., Ma, K., Zhang, L., & Li, G. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.013 · Cited by 60
Knowns and Unknowns about CAR-T Cell Dysfunction
Titov, A., Kaminskiy, Y., Ganeeva, I., Zmievskaya, E., Valiullina, A., Rakhmatullina, A., Petukhov, A., Рифкатовна, М. Р., Rizvanov, A. A., & Bulatov, E. (2022) · Cancers · doi:10.3390/cancers14041078 · Cited by 56
Dendritic Cell-Based Vaccination in Cancer: Therapeutic Implications Emerging from Murine Models
Keon, S. M., Ruiz, M. S., Gazzaniga, S., & Wainstok, R. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00243 · Cited by 57
Holuka, C., Merz, M. P., Fernandes, S. B., Charalambous, E. G., Seal, S. V., Grova, N., & Turner, J. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21145094 · Cited by 55
Paradoxical aging in HIV: immune senescence of B Cells is most prominent in young age
Rinaldi, S., Pallikkuth, S., George, V. K., de Armas, L. R., Pahwa, R., Sanchez, C. M., Pallin, M., Pan, L., Cotugno, N., Dickinson, G. M., et al. (2017) · Aging · doi:10.18632/aging.101229 · Cited by 57
Specifically differentiated T cell subset promotes tumor immunity over fatal immunity
Ramadan, A. M., Griesenauer, B., Adom, D., Kapur, R., Hanenberg, H., Liu, C., Kaplan, M. H., & Paczesny, S. (2017) · The Journal of Experimental Medicine · doi:10.1084/jem.20170041 · Cited by 57
T cell exhaustion in cancer: Mechanisms and clinical implications
Wang, J., Xu, Y., Huang, Z., & Lu, X. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26645 · Cited by 56
Li, Y., Tian, Y., Li, C., Fang, W., Li, X., Jing, Z., Yang, Z., Zhang, X., Huang, Y., Gong, J., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102518 · Cited by 57
TGF-β Sustains Tumor Progression through Biochemical and Mechanical Signal Transduction
O’Brien, R. L. F., Nixon, D. F., Brantner, C. A., Popratiloff, A. S., & Uíttenbogaart, C. H. (2018) · Cancers · doi:10.3390/cancers10060199 · Cited by 57
Crosby, E. J., Acharya, C. R., Haddad, A.-F., Rabiola, C. A., Lei, G., Wei, J.-P., Yang, X., Wang, T., Liu, C.-X., Wagner, K., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0389 · Cited by 53
CTLA4 Promotes Tyk2-STAT3–Dependent B-cell Oncogenicity
Herrmann, A., Lahtz, C., Nagao, T., Song, J. Y., Chan, W. C., Lee, H., Yue, C., Look, T., Mülfarth, R. I., Li, W., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0342 · Cited by 53
Metadata
- Authors
- Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W.
- Affiliations
- University of Michigan (US)
- University of Science and Technology of China (CN)
- Corresponding author
- Tian, Zhigang
- Zou, Weiping
- Venue
- Current Opinion in Immunology
- Publisher
- Elsevier BV
- Published
- 2013-04
- Volume
- 25
- Issue
- 2
- Pages
- 214-221
- ISSN
- 0952-7915 (ISSN-L)
- PMC
- PMC3636159
- OpenAlex
- W2050558251
- Cited by
- 752
- References
- 77
- Citations by year
- 2026: 32 · 2025: 67 · 2024: 74 · 2023: 76 · 2022: 73 · 2021: 80 · 2020: 63 · 2019: 59 · 2018: 61 · 2017: 52 · 2016: 42 · 2015: 42 · 2014: 23 · 2013: 8
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Current Opinion in Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (5t32ai007413-32)
- National Cancer Institute (R01CA123088, R01CA152470, R01CA156685, K08CA151414, R01CA099985)
- National Institute of Allergy and Infectious Diseases (T32-AI-007413)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- T cell anergy, T cell exhaustion, T cell senescence, T cell stemness, tumor microenvironment, tumor-associated antigens, immune evasion, immunosuppression, cancer immunotherapy
- MeSH terms
- Animals, Humans, Neoplasms, Stem Cells, T-Lymphocytes, Cellular Senescence, Clonal Anergy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review